MX2009004627A - Use of organic compounds. - Google Patents

Use of organic compounds.

Info

Publication number
MX2009004627A
MX2009004627A MX2009004627A MX2009004627A MX2009004627A MX 2009004627 A MX2009004627 A MX 2009004627A MX 2009004627 A MX2009004627 A MX 2009004627A MX 2009004627 A MX2009004627 A MX 2009004627A MX 2009004627 A MX2009004627 A MX 2009004627A
Authority
MX
Mexico
Prior art keywords
organic compounds
dpp
edema
progression
administering
Prior art date
Application number
MX2009004627A
Other languages
Spanish (es)
Inventor
Thomas Edward Hughes
David Grenville Holmes
Edwin Bernard Villhauer
Bork Balkan
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2009004627A publication Critical patent/MX2009004627A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Abstract

A method to prevent, delay the progression or reduce, the occurrence of edema, comprising administering a therapeutically effective amount of a DPP-IV inhibitor, or pharmaceutically acceptable salt thereof, to a patient in need thereof.
MX2009004627A 2006-11-01 2007-10-30 Use of organic compounds. MX2009004627A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86381606P 2006-11-01 2006-11-01
PCT/US2007/022902 WO2008057337A2 (en) 2006-11-01 2007-10-30 Use of dipeptidyl peptidase iv inhibitors for preventing, delaying or reducing the occurance of edema

Publications (1)

Publication Number Publication Date
MX2009004627A true MX2009004627A (en) 2009-05-22

Family

ID=39365028

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004627A MX2009004627A (en) 2006-11-01 2007-10-30 Use of organic compounds.

Country Status (9)

Country Link
EP (1) EP2079469A2 (en)
JP (1) JP2010508348A (en)
KR (1) KR20090075747A (en)
CN (1) CN101557811A (en)
AU (1) AU2007318059A1 (en)
BR (1) BRPI0717874A2 (en)
CA (1) CA2668162A1 (en)
MX (1) MX2009004627A (en)
WO (1) WO2008057337A2 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005513165A (en) * 2002-01-11 2005-05-12 ノボ　ノルディスク　アクティーゼルスカブ Methods and compositions for the treatment of diabetes, hypertension, chronic heart failure and fluid retention
US7149574B2 (en) * 2003-06-09 2006-12-12 Palo Alto Investors Treatment of conditions through electrical modulation of the autonomic nervous system
US20090253752A1 (en) * 2004-10-25 2009-10-08 Bryan Burkey Combination of dpp-iv inhibitor, ppar antidiabetic and metmorfin
WO2007035665A1 (en) * 2005-09-20 2007-03-29 Novartis Ag Use of a dpp-iv inhibitor to reduce hypoglycemic events

Also Published As

Publication number Publication date
WO2008057337A2 (en) 2008-05-15
AU2007318059A1 (en) 2008-05-15
KR20090075747A (en) 2009-07-08
CN101557811A (en) 2009-10-14
BRPI0717874A2 (en) 2013-10-29
CA2668162A1 (en) 2008-05-15
JP2010508348A (en) 2010-03-18
EP2079469A2 (en) 2009-07-22
WO2008057337A3 (en) 2008-10-16

Similar Documents

Publication Publication Date Title
WO2007149797A3 (en) Use of organic compounds
WO2008124085A3 (en) Methods of using combinations of mek and jak-2 inhibitors
MX2009009786A (en) Inhibitors of the hedgehog pathway.
MX2009004984A (en) Methods for preserving renal function using xanthine oxidoreductase inhibitors.
MY146111A (en) Acylaminopyrazoles as fgfr inhibitors
GEP20125624B (en) Pyridazine derivatives as smo inhibitors
MX350745B (en) Methods for treating fibromyalgia syndrome.
JO2848B1 (en) Organic Compounds
TW201000473A (en) Benzene or thiophene derivative and use thereof as VAP-1 inhibitor
ZA200806778B (en) N-Hydroxyacrylamide compounds
MX2010008460A (en) Thiazole derivative and use thereof as vap-1 inhibitor.
WO2007022408A3 (en) Combination methods of saha and targretin for treating cancer
UA93709C2 (en) 12-imidazolyl-1-dodecanol and use thereof in the preparation of pharmaceutical compositions
WO2011014825A3 (en) Antiangiogenic small molecules and methods of use
IL195472A0 (en) Use of allopurinol for the treatment of palmar plantar erythrodysesthesia
MX2007004020A (en) Use of renin inhibitors for the prevention or treatment of diastolic dysfunction or diastolic heart failure.
MX2009005798A (en) Stroke recovery.
UA96969C2 (en) Acylaminopyrazoles as fgfr inhibitors
TNSN08506A1 (en) Substituted carboxamides
SG141358A1 (en) Treatment of psychiatric patients with reduced heptaic function with paliperidone
MX2010002032A (en) Treatment of vasomotor symptoms.
WO2010004031A3 (en) Treatment of amyotrophic lateral sclerosis by nogo-a-antagonist
TW200806283A (en) Therapeutic methods
WO2005079769A3 (en) Piperazine derivatives for the treatment of endometriosis
MX2009004627A (en) Use of organic compounds.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal